<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03270644</url>
  </required_header>
  <id_info>
    <org_study_id>16857</org_study_id>
    <secondary_id>H8H-MC-LAHD</secondary_id>
    <nct_id>NCT03270644</nct_id>
  </id_info>
  <brief_title>A Study of Lasmiditan and Propranolol in Healthy Participants</brief_title>
  <official_title>Effect of Lasmiditan on Heart Rate and Blood Pressure in Healthy Subjects Receiving Oral Doses of Propranolol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the effects on heart rate and blood pressure when a single dose of
      lasmiditan is administered with a daily dose of propranolol. This study will also measure how
      much lasmiditan gets into the bloodstream after taking lasmiditan alone and after taking it
      together with propranolol. The study will also look at how well both drugs are tolerated.
      Information about any side effects that may occur will be collected.

      This study will last approximately 45 days including screening. This study will require 13
      days/12 nights in a Clinical Research Unit (CRU) followed by 1 follow-up appointment
      approximately 7 days after the last dose. Screening is required within 28 days prior to the
      start of the study.

      This study is for research purposes only and is not intended to treat any medical condition.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 31, 2017</start_date>
  <completion_date type="Actual">November 22, 2017</completion_date>
  <primary_completion_date type="Actual">November 22, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Mean Hourly Heart Rate</measure>
    <time_frame>Day 8, Day 9</time_frame>
    <description>Change in mean hourly heart rate as determined by Holter ambulatory monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lasmiditan, Propranolol, and Lasmiditan + Propranolol</measure>
    <time_frame>Baseline up to 48 hours postdose</time_frame>
    <description>PK: Cmax of lasmiditan, propranolol, and lasmiditan + propranolol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Concentration versus Time Curve (AUC) of Lasmiditan, Propranolol, and Lasmiditan + Propranolol</measure>
    <time_frame>Baseline up to 48 hours postdose</time_frame>
    <description>PK: AUC of lasmiditan, propranolol, and lasmiditan + propranolol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in PR Interval</measure>
    <time_frame>Day 8, Day 9</time_frame>
    <description>PR interval is the interval between the P wave and the QRS complex calculated from electrocardiogram (ECG) data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Systolic Blood Pressure</measure>
    <time_frame>Day 8, Day 9</time_frame>
    <description>Change from baseline in systolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Diastolic Blood Pressure</measure>
    <time_frame>Day 8, Day 9</time_frame>
    <description>Change from baseline in diastolic blood pressure</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lasmiditan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of lasmiditan on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propranolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Twice daily oral doses of propranolol on Days 4-10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lasmiditan + Propranolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of lasmiditan + two oral doses of propranolol on Day 9</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasmiditan</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Lasmiditan</arm_group_label>
    <arm_group_label>Lasmiditan + Propranolol</arm_group_label>
    <other_name>LY573144</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Propranolol</arm_group_label>
    <arm_group_label>Lasmiditan + Propranolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or females, as determined by medical history and physical examination

          -  Have a body mass index (BMI) of 19 to 35 kilograms per meter squared (kg/mÂ²)
             inclusive, at the time of screening

        Exclusion Criteria:

          -  Have known allergies to lasmiditan, propranolol, related compounds or any components
             of the formulation of lasmiditan or propranolol

          -  Have a history of, or electrocardiogram (ECG) findings of, clinically significant
             bradycardia, heart block, tachy or brady arrhythmias, sick sinus syndrome/sinoatrial
             block, or second or third-degree heart block, or have any other abnormality in the
             12-lead ECG that, in the opinion of the investigator, increases the risks associated
             with participating in the study

          -  Have an abnormal supine blood pressure, defined as systolic blood pressure less than
             (&lt;) 95 or greater than (&gt;) 140 millimeters of mercury (mmHg) or diastolic blood
             pressure &lt;65 or &gt;90 mmHg at screening

          -  Have a supine pulse rate of &lt;50 or &gt;90 beats per minute (bpm) at screening

          -  Have an estimated glomerular filtration rate (eGFR) of &lt;60 milliliter per minute
             (mL/min) per 1.73 meter squared (m2)

          -  Show evidence of significant active neuropsychiatric disease (for example, manic
             depressive illness, schizophrenia, depression)

          -  Show a history of central nervous system (CNS) conditions such as strokes, transient
             ischaemic attacks, significant head trauma, CNS infections, migraines, brain surgery
             or any other neurological conditions that, in the opinion of the investigator,
             increases the risk of participating in the study

          -  Are women with a positive pregnancy test or women who are lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Daytona Beach</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2017</study_first_submitted>
  <study_first_submitted_qc>August 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2017</study_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

